Published August 22, 2024 | Version v1
Publication Open

Rifampicin and its derivatives: stability, disposition, and affinity towards pregnane X receptor employing 2D and 3D primary human hepatocytes

Description

Rifampicin is a model ligand of the pregnane X receptor (PXR), the nuclear receptor involved in the regulation of cytochrome P450 3A4 (CYP3A4). Rifampicin forms several degradation products and metabolites of which 25-desacetylrifampicin is the most abundant in vivo. Here, we aimed to study both the stability and metabolism of rifampicin in media and 2D and 3D primary human hepatocytes (PHHs). Additionally, we analyzed interactions of rifampicin derivatives with PXR. We described that rifampicin gradually degrades by more than 50 % in the medium partly into quinone over 72 h. We observed 25-desacetylrifampicin in 2D PHHs but not in 3D PHHs. Contrary, rifampicin was converted into quinone in a one-direction process in media of 3D PHHs. The potency of rifampicin and its derivatives to activate human PXR was arranged as follows: 3-formylrifamycin SV > rifampicin quinone > rifampicin > rifampicin N-oxide > 25-desacetylrifampicin, respectively, but none activates mouse and rat PXR. The binding differences between rifampicin and 25-desacetylrifampicin were modeled in silico. Finally, we showed that overexpressed uptake organic anion transporting polypeptide 1B1 (OATP1B1) potentiated activation of PXR by rifampicin and rifampicin quinone, but overexpressed efflux multidrug resistance protein 1 (MDR1) decreased PXR activation by all derivatives.

Files

1-s2.0-S0006295224004830-main.pdf

Files (5.2 MB)

Name Size Download all
md5:57d73929ab09ea1e1d4a178ada9c537f
5.2 MB Preview Download

Additional details

Related works

Is published in
Journal: 10.1016/j.bcp.2024.116500 (DOI)
Is supplemented by
Dataset: https://zenodo.org/records/13737560 (URL)

Funding

Ministry of Education Youth and Sports
NETPHARM CZ.02.01.01/00/22_008/0004607
Czech Science Foundation
22-05167S
Charles University
Primus 110/13/221301

Dates

Available
2024-08-22

References

  • Biochem Pharmacol . 2024 Aug 22:229:116500. doi: 10.1016/j.bcp.2024.116500.